New Meds and Tech from the PES Drugs & Therapeutics Committee – Qsymia®

New Meds and Tech from PES Drugs and Therapeutics committee In June 2022, the Food and Drug Administration (FDA) approved a supplemental indication for Qsymia (phentermine…

Read More

New Meds and Tech from the PES Drugs & Therapeutics Committee – FreeStyle Libre 3™

New Meds and Tech from PES Drugs and Therapeutics committee The FreeStyle Libre 3 is the third generation of Abbot Laboratories’ continuous glucose monitoring system intended…

Read More

New Meds and Tech from the PES Drugs & Therapeutics Committee – Omnipod® 5

New Meds and Tech from PES Drugs and Therapeutics committee The Omnipod 5 (Insulet Inc) is a hybrid closed-loop system approved by the FDA on January…

Read More

New Meds and Tech from the PES Drugs & Therapeutics Committee – GnRH agonists

New Meds and Tech from PES Drugs and Therapeutics committee PES Drug Alert – GnRH agonists On July 1, 2022 the Food and Drug Administration (FDA)…

Read More

New Meds and Tech from the PES Drugs & Therapeutics Committee – VOXZOGO

New Meds and Tech from PES Drugs and Therapeutics committee VOXZOGOTM Anna Ryabets-Lienhard, DO On November 19, 2021, the FDA approved VOXZOGOTM (vosoritide) for the treatment…

Read More

New Meds and Tech from the PES Drugs & Therapeutics Committee – Skytrofa

New Meds and Tech from PES Drugs and Therapeutics committee SKYTROFA® Anna Ryabets-Lienhard, DO, Christine Yu, MD, Emily Breidbart, MD   In August 2021, FDA approved…

Read More

New Meds and Tech from PES Drugs and Therapeutics Committee Evolocumab

EVOLOCUMAB (REPATHA) Brenda Kohn MD, Dania Al-Hamad MD, Ambika P. Ashraf MD On September 24, 2021, Amgen announced that the FDA approved evolocumab (Repatha) as an adjunct…

Read More

New Ready-to-Use Glucagon Preparation: Zegalogue

Prepared on behalf of the PES Drugs and Therapeutics Committee by Kristal Matlock, MD, Dania Al-Hamad, MD, Vandana Raman, MD and Amit Lahoti, MD FDA approval…

Read More

New Meds and Tech from PES Drugs and Therapeutics Committee

Brief Therapeutic Update from PES Drugs and Therapeutics Committee (THYQUIDITYTM) THYQUIDITYTM is a liquid levothyroxine preparation that is FDA approved for (i) treatment of congenital or…

Read More

New Meds and Tech from PES Drugs and Therapeutics Committee

This content is for PES Members.

Log In

Not a member yet? Join the largest Pediatric Endocrine community and unlock a host of tools, resources, and enhance your network! Click here to learn more.

Read More